Department of Chemistry and Industrial Chemistry, Faculty of Pure and Applied Sciences, PMB 1530, Kwara State University, Malete, Nigeria; Department of Chemistry, Faculty of Science, University of Lagos, Nigeria; National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, MS 38677, United States.
Department of Chemistry, Faculty of Science, University of Lagos, Nigeria.
Fitoterapia. 2024 Jul;176:106037. doi: 10.1016/j.fitote.2024.106037. Epub 2024 May 25.
In this study, bioactive compounds were isolated and characterized from the leaves and root-barks extracts of S.latifolius, with subsequent in vitro experimental investigations for antihyperglycemic potentials on α-amylase and α-glucosidase enzymes. Thirteen bioactive compounds were identified, including 10-Hydroxystrictosamide (2) and Quinovic acid-3-O-α-L-rhamnosyl-28-O-β-d-glucopyranosyl ester (8), using chromatographic, nuclear magnetic resonance spectroscopy (NMR), and mass spectrometry (MS) techniques. Experimental assays revealed that compounds 1-4 exhibited potent inhibition of α-amylase and α-glucosidase, with compound 2 demonstrating the most potent α-amylase inhibition (IC value of 0.52 ± 0.003 μg/mL). Compound 8 showed a lower IC value (0.098 ± 0.016 μg/mL) against α-glucosidase compared to compound 2 and acarbose. Synergistic effects among the compounds could enhance their inhibitory actions on the enzymes, positioning them as potential anti-hyperglycemia agents. Compound 2 displayed the highest binding affinity (-7.970 kcal/mol) when docked against α-amylase (PDB ID: 2QV4), comparable to acarbose (-8.515 kcal/mol). It also ranked among the top ligands against α-glucosidase (PDB ID 3TOP), although compound 13 and acarbose had higher docking scores. All compounds exhibited ideal ADMET properties, suggesting good bioavailability and low toxicity. In conclusion, the isolated compounds exhibit promising antihyperglycemic potential and favourable safety profiles for further exploration.
在这项研究中，从 S.latifolius 的叶和根皮提取物中分离和鉴定了生物活性化合物，并随后进行了体外实验研究，以评估它们对α-淀粉酶和α-葡萄糖苷酶的抗高血糖潜力。使用色谱、核磁共振波谱（NMR）和质谱（MS）技术，鉴定出 13 种生物活性化合物，包括 10-羟基斯特立克酰胺（2）和喹诺酸-3-O-α-L-鼠李糖基-28-O-β-D-吡喃葡萄糖苷酯（8）。实验结果表明，化合物 1-4 对α-淀粉酶和α-葡萄糖苷酶表现出强烈的抑制作用，其中化合物 2 对α-淀粉酶的抑制作用最强（IC 值为 0.52±0.003μg/mL）。与化合物 2 和阿卡波糖相比，化合物 8 对α-葡萄糖苷酶的 IC 值（0.098±0.016μg/mL）较低。这些化合物之间的协同作用可能会增强它们对酶的抑制作用，使它们成为有潜力的抗高血糖药物。当与α-淀粉酶（PDB ID：2QV4）对接时，化合物 2 表现出最高的结合亲和力（-7.970 kcal/mol），与阿卡波糖（-8.515 kcal/mol）相当。它在与α-葡萄糖苷酶（PDB ID 3TOP）的对接中也排在前几位，尽管化合物 13 和阿卡波糖的对接得分更高。所有化合物均表现出理想的 ADMET 性质，提示它们具有良好的生物利用度和低毒性。综上所述，这些分离出的化合物具有潜在的抗高血糖作用和良好的安全性，值得进一步研究。
